BMJ  1991;303:821-824 (5 October), doi:10.1136/bmj.303.6806.821

Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.

A J Apperloo, D de Zeeuw, H E Sluiter, P E de Jong

Department of Medicine, State University Hospital, Groningen, The Netherlands.

OBJECTIVE--To compare the antihypertensive, renal haemodynamic and antiproteinuric effect of enalapril and atenolol in patients with proteinuria of non-diabetic origin. DESIGN--Prospective, double blind, randomised 16 week study after a pretreatment period of at least three weeks. SETTING--Outpatient nephrology and hypertension unit. PATIENTS--27 patients with proteinuria (greater than 300 mg protein/day) of non-diabetic origin, moderately impaired renal function (creatinine clearance 30-90 ml/min), and a pretreatment diastolic blood pressure of greater than 80 mm Hg. INTERVENTIONS--Treatment with enalapril (10 mg/day, adjusted between 5 and 40 mg, if necessary) or atenolol (50 mg/day, adjusted between 25 and 100 mg if necessary) titrated against a target fall in diastolic blood pressure to less than 95 mm Hg or of greater than 10 mm Hg, or both. MAIN OUTCOME MEASURES--Blood pressure, renal haemodynamics, and urinary protein excretion. RESULTS--No differences were detected between the two groups before treatment. The falls in systolic and diastolic blood pressures during treatment were not significantly different between both groups. Proteinuria fell slightly with atenolol but significantly more with enalapril (mean change -0.38 (95% confidence interval -0.78 to 0.03) v -1.2 (-1.70 to -0.69) g/day respectively, p less than 0.02) as did filtration fraction (mean change -1.8 (-2.9 to -0.7) v -3.8 (-4.9 to -2.8)% respectively. Serum potassium concentration increased with enalapril (mean change 0.63 (SD 0.51) v 0.19 (0.47) mmol/l, p less than 0.05). CONCLUSIONS--Enalapril lowers proteinuria more than atenolol in patients with non-diabetic renal disease despite a similar blood pressure lowering effect of both drugs, and its antiproteinuric effect seems to be associated with the characteristic renal haemodynamic effect of angiotensin converting enzyme inhibitors.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Thompson, J., Reid, M., Hambleton, I., Serjeant, G. R. (2007). Albuminuria and Renal Function in Homozygous Sickle Cell Disease: Observations From a Cohort Study. Arch Intern Med 167: 701-708 [Abstract] [Full text]  
  • Bos, H., Laverman, G. D, Henning, R. H, Tiebosch, A. T., de Jong, P. E, de Zeeuw, D., Navis, G. (2003). Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats. Journal of Renin-Angiotensin-Aldosterone System 4: 106-112 [Abstract]  
  • ter Wee, P. M., Epstein, M. (1993). Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Chronic Renal Disease. Arch Intern Med 153: 1749-1759 [Abstract]  
  • Gansevoort, R. T., Apperloo, A. J., Heeg, J. E., de Jong, P. E., de Zeeuw, D. (1992). The Antiproteinuric Effect of Antihypertensive Agents in Diabetic Nephropathy. Arch Intern Med 152: 2137-2138 [Abstract]  
Access jobs at BMJ Careers
Whats new online at Student BMJ